An update on the role of immunotherapy in reproductive failure

Immunology and Allergy Clinics of North America

Volumn 22, Issue 3, 2002, Pages 623-642

  Stephenson, Mary D ^a,b   Ensom, Mary H H ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

CLINICAL TRIAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; FEMALE; FERTILIZATION IN VITRO; HUMAN; IMMUNOTHERAPY; LUNG EDEMA; LUNG TOXICITY; PREGNANCY; PRIORITY JOURNAL; RASH; RECURRENT DISEASE; REPRODUCTION; REVIEW; RISK BENEFIT ANALYSIS; SPONTANEOUS ABORTION;

EID: 0036694448     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8561(02)00004-8     Document Type: Review

References (135)

1. Ohno M, Maeda T, Matsunobu A. A cytogenetic study of spontaneous abortions with direct analysis of chorionic villi. Obstet Gynecol 1991;77:394-8.
2. Jacobs PA, Hassold TJ. Chromosome abnormalities: origin and etiology in abortions and livebirths. In: Vogel F, Sperling K, editors. Human genetics. Berlin: Verlag; 1987. p. 233-44.
3. Simpson JL. Incidence and timing of pregnancy losses: relevance to evaluating safety of early prenatal diagnosis. Am J Med Gen 1990;35:165-73.
4. Plachot M. Chromosome analysis of spontaneous abortions after IVF: a European survey. Hum Reprod 1989;4:425-9.
5. Stephenson MD, Awartani KA, Robinson WP. Cytogenetic analysis of miscarriages from couples with recurrent miscarriage: a case-control study. Hum Reprod 2002;17:446-51.
6. Stephenson MD. Frequency of factors associated with habitual abortion in 197 couples. Fertil Steril 1996;66:25-9.
7. Beer AE, Quebbeman JF, Ayers JWT, et al. Major histocompatibility complex antigens, maternal and paternal immune responses, and chronic habitual abortions in humans. Am J Obstet Gynecol 1981;141:987-97.
8. Hill JA, Choi BC. Immunodystrophism: evidence for a novel alloimmune hypothesis for recurrent pregnancy loss involving Th1-type immunity to trophoblast. Semin Reprod Med 2000; 18:401-5.
9. Stephenson MD. Recurrent pregnancy loss: clinical evidence for suboptimal implantation. Infertil Reprod Med Clin North Am 2001;12:447-61.
10. Anonymous. Assisted reproductive technology in the United States: 1996 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry. Fertil Steril 1999;71:789-807.
11. Erenus M, Zouves C, Rajamahendran P, et al. The effect of embryo quality on subsequent pregnancy rates after in vitro fertilization. Fertil Steril 1991;56:707-10.
12. Gonen T, Casper R. Prediction of implantation by the sonographic appearance of the endometrium during controlled ovarian stimulation for in vitro fertilization (IVF). J In Vitro Fert Embryo Transf 1990;7:146-52.
13. Templeton A, Morris JK. Reducing the risk of multiple births by transfer of two embryos after in vitro fertilization. N Engl J Med 1998;339:573-7.
14. Bronson R. Immunology and reproductive medicine. Hum Reprod 1995;10:755-7.
15. Cauchi MN, Lim D, Young DE, et al. Treatment of recurrent aborters by immunization with paternal cells: controlled trial. Am J Reprod Immunol 1991;25:16-7.
16. Gatenby PA, Cameron K, Simes RJ, et al. Treatment of recurrent spontaneous abortion by immunization with paternal lymphocytes: results of a controlled trial. Am J Reprod Immunol 1993;29:88-94.
17. Ho HN, Gill TJ, Hsieh HJ, et al. Immunotherapy for recurrent spontaneous abortion in a Chinese population. Am J Reprod Immunol 1991;25:10-5.
18. Jeng GT, Scott JR, Burmeister LF. A comparison of meta-analytic results using literature vs individual patient data. JAMA 1995;274:830-6.
19. Mowbray JF, Liddell H, Gibbings C, et al. Controlled trial of treatment of recurrent spontaneous abortion by immunisation with paternal cells. Lancet 1985;1:941-3.
20. Ober C, Karrison T, Odem RR, et al. Mononuclear cell immunization in prevention of recurrent miscarriage: a randomised trial. Lancet 1999;354:365-9.
21. Recurrent Miscarriage Immunotherapy Trialist Group. Worldwide collaborative observational study and meta-analysis on allogenic leukocyte immunotherapy for recurrent spontaneous abortion. Am J Reprod Immunol 1994;32:55-72.
22. Bussel JB, Berkowitz RL, McFarland JG, et al. Antenatal treatment of neonatal alloimmune thrombocytopenia. N Engl J Med 1988;319:1374-8.
23. Carreras LO, Perez GN, Vega HR, et al. Lupus anticoagulant and recurrent fetal loss: successful treatment with gammaglobulin. Lancet 1988;2:393-4.
24. Mueller-Eckhardt G, Heine O, Neppert J, et al. Prevention of recurrent spontaneous abortion by intravenous immunoglobulin. Vox Sang 1989;56:151-4.
25. De Placido G, Zullo F, Cappiello F, et al. Immunological treatment of implantation failure. Ann N Y Acad Sci 1991;622:291-5.
26. Anonymous. Outbreak of hepatitis C associated with intravenous immunoglobulin administration-United States, October 1993-June 1994. JAMA 1994;272:424-5.
27. Bresee JS, Mast EE, Coleman PJ, et al. Hepatitis C virus infection associated with administration of intravenous immune globulin: a cohort study. JAMA 1996;276:1563-7.
28. Eibl MM, Wedgwood RJ. Intravenous immunoglobulin: a review. Immunodefic Rev 1989; 1(suppl):1-42.
29. Biesert L. Virus validation studies of immunoglobulin preparations. Clin Exp Rheumatol 1996;14(suppl):S47-52.
30. Morgenthaler J, Omar A. Partitioning and inactivation of viruses during isolation of albumin and immunoglobulins by cold ethanol fractionation. In: Brown F, editor. Virological safety aspects of plasma derivatives, vol. 81. Basel: Karger; 1993. p. 185-90.
31. Yei S, Yu MW, Tankersley DL. Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma. Transfusion 1992;32:824-8.
32. Nydegger UE. Safety and side effects of i.v. immunoglobulin therapy. Clin Exp Rheumatol 1996;14(suppl):S53-57.
33. Johnson RT, Gibbs CJ. Creutzfeldt-Jakob Disease and related transmissible spongiform encephalopathies. N Engl J Med 1998;339:1994-2004.
34. Montanaro A, Pirofsky B. Prolonged interval high-dose intravenous immunoglobulin in patients with primary immunodeficiency states. Am J Med 1984;76:67-72.
35. Noya FJ, Rench MA, Courtney JT, Feldman S, Baker CJ. Pharmacokinetics of intravenous immunoglobulin in very low birth weight neonates. Pediatr Infect Dis J 1989;8:759-63.
36. Pirofsky B, Campbell SM, Montanaro A. Individual patient variations in the kinetics of intravenous immune globulin administration. J Clin Immunol 1982;2(suppl):S7-S14.
37. Pirofsky B, Kinzey DM. Intravenous immune globulins: a review of their uses in selected immunodeficiency and autoimmune diseases. Drugs 1992;43:6-14.
38. Schiff RI. Half-life and clearance of pH 6.8 and pH 4.25 immunoglobulin G intravenous preparations in patients with primary disorders of humoral immunity. Rev Infect Dis 1986; 8(suppl):S449-456.
39. Stiehm ER. Human intravenous immunoglobulin in primary and secondary antibody deficiencies. Pediatr Infect Dis J 1997;16:696-707.
40. Boshkov LK, Kelton JG. Use of intravenous gammaglobulin as an immune replacement and an immune suppressant. Transf Med Rev 1989;3:82-120.
41. Ensom MH, Amos C, Pi D, et al. Pharmacokinetics of intravenous immunoglobulin (IVIG) in patients with hypogammaglobulinemia [abstract]. Pharmacotherapy 2000;21:1296.
42. Pirofsky B. Intravenous immune globulin therapy in hypogammaglobulinemia: a review. Am J Med 1984;76:53-60.
43. Hagenbeek A, Brummelhuis GJ, Donkers A, et al. Rapid clearance of cytomegalovirus-specific IgG after repeated intravenous infusions of human immunoglobulin into allogeneic bone marrow transplant recipients. J Infect Dis 1987;155:897-902.
44. Kinney J, Mundorf L, Gleason C, et al. Efficacy and pharmacokinetics of intravenous immune globulin administration to high-risk neonates. Am J Dis Child 1991;145:1233-8.
45. Rand KH, Houck H, Ganju A, et al. Pharmacokinetics of cytomegalovirus specific IgG antibody following intravenous immunoglobulin in bone marrow transplant patients. Bone Marrow Transplant 1989;4:679-83.
46. Rand KH, Gibbs K, Derendorf H, et al. Pharmacokinetics of intravenous immunoglobulin (Gammagard) in bone marrow transplant patients. J Clin Pharmacol 1991;31:1151-4.
47. Thurmann PA, Sonnenburg-Chatzopoulos C, et al. Pharmacokinetic characteristics and tolerability of a novel intravenous immunoglobulin preparation. Eur J Clin Pharmacol 1995;49:237-42.
48. van Engelen BG, Renier WO, Weemaes CM, et al. High-dose intravenous immunoglobulin treatment in cryptogenic West and Lennox-Gastaut syndrome: an add-on study. Eur J Pediatr 1994;153:762-9.
49. Ochs HD, Fischer SH, Wedgwood RJ, et al. Comparison of high-dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases. Am J Med 1984;76:78-82.
50. Lockitch G, Halstead AC, Quigley G, et al. Age- and sex-specific pediatric reference intervals: study design and methods illustrated by measurement of serum proteins with the Behring LN Nephelometer. Clin Chem 1988;34:1618-21.
51. Nolte MT, Pirofsky B, Gerritz GA, Golding B. Intravenous immunoglobulin therapy for antibody deficiency. Clin Exp Immunol 1979;36:237-43.
52. Liese JG, Wintergerst U, Tympner KD, et al. High- vs. low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia. Am J Dis Child 1992; 146:335-9.
53. Roifman CH, Levison H, Gelfand EW. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet 1987;1:1075-7.
54. Haeney M. Intravenous immune globulin in primary immunodeficiency. Clin Exp Immunol 1994;97(suppl):11-5.
55. Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog Allergy 1969;13:1-1110.
56. Christiansen OB, Mathiesen O, Lauritsen JG, et al. Intravenous immunoglobulin treatment of women with multiple miscarriages. Hum Reprod 1992;7:718-22.
57. Kluter H, Germer U, Gortner L, et al. Coincidence of neonatal alloimmune thrombocytopenia and maternal anti-D immunization: case report. Br J Haematol 1998;102:1383-4.
58. Kwak JY, Quilty EA, Gilman-Sachs A, et al. Intravenous immunoglobulin infusion therapy in women with recurrent spontaneous abortions of immune etiologies. J Reprod Immunol 1995; 28:175-88.
59. Marzusch K, Schnaidt M. Antenatal treatment of alloimmune thrombocytopenia. Obstet Gynecol 1992;80:1057.
60. Nicolini U, Tannirandom Y, Gonzalez P, et al. Continuing controversy in alloimmune thrombocytopenia: fetal hyperimmunoglobulinemia fails to prevent thrombocytopenia. Am J Obstet Gynecol 1990;163:1144-6.
61. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999;340:227-8.
62. Sell S, Fahey JL. Relationship between γ-gloublin metabolism and low serum γ-globulin in germfree mice. J Immunol 1964;93:81-7.
63. Amran D, Renz H, Lack G, et al. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol 1994;73:180-6.
64. Mouthon L, Kaveri SV, Spalter SH, et al. Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol 1996;104(suppl):3-9.
65. Hurez V, Kaveri SV, Mouhoub A, et al. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. Ther Immunol 1994;1:269-77.
66. Ravetch JV. Fc receptors. Cur Opin Immunol 1997;9:121-5.
67. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992;326: 107-16.
68. Bussel JB. Modulation of Fc receptor clearance and antiplatelet antibodies as a consequence of intravenous immune globulin infusion in patients with immune thrombocytopenic purpura. J Allergy Clin Immunol 1989;84:566-77.
69. Debre M, Bonnet MC, Fridman WH, et al. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 1993;342:945-9.
70. Kondo N, Ozawa T, Mushiake K, et al. Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin. J Clin Immunol 1991;11:152-8.
71. Lacroix-Desmazes S, Mouthon L, Spalter SH, et al. Immunoglobulins and the regulation of autoimmunity through the immune network. Clin Exp Rheumatol 1996;14(suppl 15):S9-15.
72. Basta M, Kirshbom P, Frank MM, et al. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin: attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest 1989;84:1974-81.
73. Basta M, Fries LF, Frank MM. High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood 1991;77:376-80.
74. Ruiz JE, Kwak JY, Baum L, et al. Intravenous immunoglobulin inhibits natural killer cell activity in vivo in women with recurrent spontaneous abortion. Am J Reprod Immunol 1996;35:370- 5.
75. Kwak JY, Kwak FM, Ainbinder SW, et al. Elevated peripheral blood natural killer cells are effectively downregulated by immunoglobulin G infusion in women with recurrent spontaneous abortions. Am J Reprod Immunol 1996;35:363-9.
76. + cells can predict pregnancy outcome. Am J Reprod Immunol 1995;33:40-6.
77. Hill JA, Polgar K, Anderson DJ. T-helper 1-type immunity to trophoblast in women with recurrent spontaneous abortion. JAMA 1995;273:1933-6.
78. U.S. Preventive Services Task Force Guide to Clinical Preventive Services. Report of the U.S. Preventive Services Task Force. 2nd edition. Baltimore: Williams & Wilkins; 1996. p. 861-2.
79. Blanchette VS, Chen L, de Friedberg ZS, et al. Alloimmunization to the PIAI platelet antigen: results of a prospective study. Br J Haematol 1990;74:209-15.
80. Herman JH, Jumbelic MI, Ancona RJ, et al. In utero cerebral hemorrhage in alloimmune thrombocytopenia. Am J Pediatr Hematol Oncol 1986;8:312-7.
81. Williamson LM, Hackett GA, Rennie JM, et al. Determination of the natural history of neonatal alloimmune thrombocytopenia (NAITP) by antinatal screening. Blood 1995;86S:538a.
82. Mir N, Samson D, House MJ, et al. Failure of antenatal high-dose immunoglobulin to improve fetal platelet count in neonatal allo-immune thrombocytopenia. Vox Sang 1988;55:188-9.
83. Pearlman SA, Meek RS, Cowchock FS, et al. Neonatal alloimmune thrombocytopenia after maternal immunization with paternal mononuclear cells: successful treatment with intravenous gamma globulin. Am J Perinatol 1992;9:448-51.
84. Wenstrom KD, Weiner CP, Williamson RA. Antenatal treatment of fetal alloimmune thrombocytopenia. Obstet Gynecol 1992;80:433-5.
85. Lynch L, Bussel JB, McFarland JG, et al. Antenatal treatment of alloimmune thrombocytopenia. Obstet Gynecol 1992;80:67-71.
86. Kroll H, Kiefel V, Giers G, et al, Maternal intravenous immunoglobulin treatment does not prevent intracranial haemorrhage in fetal alloimmune thrombocytopenia. Transfus Med 1994; 4:293-6.
87. Murphy MF, Waters AH, Doughty HA, et al. Antenatal management of fetomaternal alloimmune thrombocytopenia-report of 15 affected pregnancies. Transf Med 1994;4:281-92.
88. Dickinson JE, Marshall LR, Phillips JM, et al. Antenatal diagnosis and management of fetomaternal alloimmune thrombocytopenia. Am J Perinatol 1995;12:333-5.
89. Bussel JB, Berkowitz RL, Lynch L, et al. Antenatal management of alloimmune thrombocytopenia with intravenous gamma-globulin: a randomized trial of the addition of low-dose steroid to intravenous gamma-globulin. Am J Obstet Gynecol 1996;174:1414-23.
90. Giers G, Hoch J, Bauer H, et al. Therapy with intravenous immunoglobulin G (ivIgG) during pregnancy for fetal alloimmune (HPA-1a(Zwa)) thrombocytopenic purpura. Prenat Diagn 1996; 16:495-502.
91. Kanhai HH, Porcelijn L, van Zoeren D, et al. Antenatal care in pregnancies at risk of alloimmune thrombocytopenia: report of 19 cases in 16 families. Eur J Obstet Gynecol Reprod Biol 1996;68:67-73.
92. Komfeld I, Wilson RD, Ballem P, et al. Antenatal invasive and noninvasive management of alloimmune thrombocytopenia. Fetal Diagn Ther 1996;11:210-7.
93. Kaplan C, Murphy MF, Kroll H, et al. Feto-maternal alloimmune thrombocytopenia: antenatal therapy with IvIgG and steroids-more questions than answers. European Working Group on FMAIT. Br J Haematol 1998;100:62-5.
94. Bussel JB, Berkowitz RL, McFarland JG. Maternal IVIG in neonatal alloimmune thrombocytopenia. Br J Haematol 1997;98:493-4.
95. Silver RM, Porter TF, Branch DW, et al. Neonatal alloimmune thrombocytopenia: antenatal management. Am J Obstet Gynecol 2000;182:1233-8.
96. Wilson W, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42:1309-11.
97. Kutteh WH, Rote NS, Silver R. Antiphospholipid antibodies and reproduction: the antiphospholipid antibody syndrome. Am J Reprod Immunol 1999;41:133-52.
98. Triplett DA. Antiphospholipid antibodies: proposed mechanisms of action. Am J Reprod Immunol 1992;28:211-5.
99. Out HJ, Kooijman CD, Bruinse HW, et al. Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies. Eur J Obstet Gynecol Reprod Bio 1991;41:179-86.
100. Adler RR, Ng AK, Rote NS. Monoclonal antiphosphatidylserine antibody inhibits intercellular fusion of the choriocarcinoma line JAR. Biol Repro 1995;53:905-10.
101. Cowchock FS, Reece EA, Balaban D, Branch DW, Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol 1992;166:1318-23.
102. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174:1584-9.
103. Rai R, Cohen H, Dave M, et al. Randomized controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997;314:253-7.
104. Lockwood CJ, Rand JH. The immunobiology and obstetrical consequences of antiphospholipid antibodies. Obstet Gynecol Surv 1994;49:432-41.
105. Rai RS, Clifford K, Cohen H, et al. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod 1995;10: 3301-4.
106. Backos M, Rai R, Baxter N, et al. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin. Br J Obstet Gynaecol 1999;106:102-7.
107. Scott JR, Branch DW, Kochenour NK, et al. Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy loss caused by antiphospholipid antibodies and Rh immunization. Am J Obstet Gynecol 1988;159:1055-6.
108. Francois A, Freund M, Daffos F, et al. Repeated fetal losses and the lupus anticoagulant. Ann Intern Med 1988;109:993-4.
109. Wapner RJ, Cowchock FS, Shapiro SS. Successful treatment in two women with antiphospholipid antibodies and refractory pregnancy losses with intravenous immunoglobulin infusions. Am J Obstet Gynecol 1989;161:1271-2.
110. Parke A, Maier D, Wilson D, et al. Intravenous gamma-globulin, antiphospholipid antibodies, and pregnancy. Ann Intern Med 1989;110:495-6.
111. Katz VL, Thorp Jr. JM, Watson WJ, et al. Human immunoglobulin therapy for preeclampsia associated with lupus anticoagulant and anticardiolipin antibody. Obstet Gynecol 1990;76: 986-8.
112. Kaaja R, Julkunen H, Ammala P, et al. Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy losses associated with antiphospholipid antibodies. Acta Obstet Gynecol Scand 1993;72:63-6.
113. Arnout J, Spitz B, Wittevrongel C, et al. High-dose intravenous immunoglobulin treatment of a pregnant patient with an antiphospholipid syndrome: immunological changes associated with a successful outcome. Thromb Haemost 1994;71:741-7.
114. Spinnato JA, Clark AL, Pierangeli SS, et al. Intravenous immunoglobulin therapy for the antiphospholipid syndrome in pregnancy. Am J Obstet Gynecol 1995;172:690-4.
115. Valensise H, Vaquero E, De Carolis C, et al. Normal fetal growth in women with antiphospholipid syndrome treated with high-dose intravenous immunoglobulin (IVIG). Prenat Diagn 1995; 15:509-17.
116. Marzusch K, Dietl J, Klein R, et al. Recurrent first trimester spontaneous abortion associated with antiphospholipid antibodies: a pilot study of treatment with intravenous immunoglobulin. Acta Obstet Gynecol Scand 1996;75:922-6.
117. Katano K, Aoki K, Ogasawara M, et al. Postpartum thrombosis after a successful pregnancy in a recurrent aborter strongly positive for antiphospholipid antibodies. Acta Obstet Gynecol Scand 1998;77:354-6.
118. Clark AL, Branch DW, Silver RM, et al. Pregnancy complicated by the antiphospholipid syndrome: outcomes with intravenous immunoglobulin therapy. Obstet Gynecol 1999;93:437-41.
119. Branch DW, Peaceman AM, Druzin M, et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. Am J Obstet Gynecol 2000;182:122-7.
120. Parke A. The role of IVIG in the management of patients with antiphospholipid antibodies and recurrent pregnancy losses. Clin Rev Allergy Immunol 1992;10:105-18.
121. Coulam C, Peters A, McIntyre J, et al. The use of IVIG for the treatment of recurrent spontaneous abortion. Immunotherapy with intravenous immunoglobulins. San Diego: Academic Press; 1991. p. 395-400.
122. German RSA/IVIG Group. Intravenous immunoglobulin in the prevention of recurrent miscarriage. Br J Obstet Gynaecol 1994;101:1072-7.
123. Coulam CB, Krysa L, Stem JJ, et al. Intravenous immunoglobulin for treatment of recurrent pregnancy loss. Am J Reprod Immunol 1995;34:333-7.
124. Perino A, Vassiliadis A, Vucetich A, et al. Short-term therapy for recurrent abortion using intravenous immunoglobulins: results of a double-blind placebo-controlled Italian study. Hum Reprod 1997;12:2388-92.
125. Stephenson MD, Dreher K, Houlihan E, et al. Prevention of unexplained recurrent spontaneous abortion using intravenous immunoglobulin: a prospective, randomized, double-blinded, placebo-controlled trial. Am J Reprod Immunol 1998;39:82-8.
126. Jablonowska B, Selbing A, Palfi M, et al. Prevention of recurrent spontaneous abortion by intravenous immunoglobulin: a double-blind placebo-controlled study. Hum Reprod 1999;14: 838-41.
127. Christiansen OB, Mathiesen O, Husth M, et al. Placebo-controlled trial of treatment of unexplained secondary recurrent spontaneous abortions and recurrent late spontaneous abortions with i.v. immunoglobulin. Hum Reprod 1995;10:2690-5.
128. Stephenson MD. Intravenous immunoglobulin (IVIG) for treatment of unexplained secondary recurrent spontaneous miscarriage: a prospective, randomized, double-blinded, placebocontrolled trial. Frontiers in Fetal Health 2001;3:105-6.
129. De Placido G, Zullo F, Mollo A, et al. Intravenous immunoglobulin (IVIG) in the prevention of implantation failures. Ann N Y Acad Sci 1994;734:232-4.
130. Coulam CB, Krysa LW, Bustillo M. Intravenous immunoglobulin for in-vitro fertilization failure. Hum Reprod 1994;9:2265-9.
131. Balasch J, Creus M, Fabregues F, et al. Intravenous immunoglobulin preceding in vitro fertilization-embryo transfer for patients with repeated failure of embryo transfer. Fertil Steril 1996; 65:655-8.
132. Sher G, Maassarani G, Zouves C, et al. The use of combined heparin/aspirin and immunoglobulin G therapy in the treatment of in vitro fertilization patients with antithyroid antibodies. Am J Reprod Immunol 1998;39:223-5.
133. Sher G, Zouves C, Feinman M, et al. A rational basis for the use of combined heparin/aspirin and IVIG immunotherapy in the treatment of recurrent IVF failure associated with antiphospholipid antibodies. Am J Reprod Immunol 1998;39:391-4.
134. Sher G, Matzner W, Feinman M, et al. The selective use of heparin/aspirin therapy, alone or in combination with intravenous immunoglobulin G, in the management of antiphospholipid antibody-positive women undergoing in vitro fertilization. Am J Reprod Immunol 1998;40: 74-82.
135. Stephenson MD, Fluker MR. Treatment of repeated unexplained in vitro fertilization failure with intravenous immunoglobulin: a randomized, placebo-controlled Canadian trial. Fertil Steril 2000;74:1108-13.